The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells

Increasing evidence suggests that brain tumors arise from the transformation of neural stem/precursor/progenitor cells. Much current research on human brain tumors is focused on the stem-like properties of glioblastoma. Here we show that anaplastic lymphoma kinase (ALK) and its ligand pleiotrophin a...

Full description

Saved in:
Bibliographic Details
Published inOncogene Vol. 33; no. 17; pp. 2236 - 2244
Main Authors Koyama-Nasu, R, Haruta, R, Nasu-Nishimura, Y, Taniue, K, Katou, Y, Shirahige, K, Todo, T, Ino, Y, Mukasa, A, Saito, N, Matsui, M, Takahashi, R, Hoshino-Okubo, A, Sugano, H, Manabe, E, Funato, K, Akiyama, T
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 24.04.2014
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Increasing evidence suggests that brain tumors arise from the transformation of neural stem/precursor/progenitor cells. Much current research on human brain tumors is focused on the stem-like properties of glioblastoma. Here we show that anaplastic lymphoma kinase (ALK) and its ligand pleiotrophin are required for the self-renewal and tumorigenicity of glioblastoma stem cells (GSCs). Furthermore, we demonstrate that pleiotrophin is transactivated directly by SOX2, a transcription factor essential for the maintenance of both neural stem cells and GSCs. We speculate that the pleiotrophin-ALK axis may be a promising target for the therapy of glioblastoma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0950-9232
1476-5594
DOI:10.1038/onc.2013.168